Cost sharing for preferred branded drugs in Medicare Part D

14 February 2025 - Most individuals in the US are concerned about prescription drug affordability. ...

Read more →

Cell and gene therapies - improving access and outcomes for Medicare and Medicaid beneficiaries

1 February 2025 - State Medicaid agencies can now apply to participate in a new model that supports voluntary, outcomes-based agreements ...

Read more →

Ozempic among the next drugs up for Medicare price negotiations

17 January 2025 - List of drugs account for $41 billion in annual Medicare spending, Biden administration says. ...

Read more →

HHS announces cost savings for 64 prescription drugs thanks to the Medicare Prescription Drug Inflation Rebate Program established by the Biden-Harris Administration’s lower cost prescription drug law

20 December 2024 - Under the Inflation Reduction Act, some people with Medicare will pay less for some Part B ...

Read more →

Biden-Harris Administration takes next steps to increase access to sickle cell disease treatments

4 December 2024 - Today, the Biden-Harris Administration announced that two drug manufacturers with FDA approved gene therapies for sickle ...

Read more →

Biden-Harris Administration announces Medicare Advantage and Medicare Part D prescription drug proposals that aim to improve care and access for enrollees

26 November 2024 - Today, the CMS is proposing actions in the Medicare Advantage and Medicare Part D prescription drug programs ...

Read more →

Representativeness of studies required under Medicare’s coverage with evidence development program

13 November 2024 - Medicare beneficiaries are often inadequately represented in clinical studies supporting US Food and Drug Administration medical product ...

Read more →

The sickest patients are fleeing private Medicare plans costing taxpayers billions

11 November 2024 - Medicare Advantage patients in the last year of life were far more likely to switch to traditional ...

Read more →

I’m the director of the Center for Medicare. Here’s how we executed the first round of drug price negotiation.

29 October 2024 - The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription ...

Read more →

Alhemo recommended for European approval as first once daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors

18 October 2024 - Novo Nordisk today announced that the EMA's CHMP has adopted a positive opinion, recommending approval of ...

Read more →

Medicare’s first round of drug price negotiation - measuring success

16 October 2024 - The Federal Government has proven that it can navigate the difficult process of identifying drugs for price ...

Read more →

A roadmap for improving Medicare’s application of coverage with evidence development

13 September 2024 - The Centers for Medicare and Medicaid Services’ coverage with evidence development policy allows the agency to provide ...

Read more →

How to tell if Biden drove a hard bargain in Medicare drug price negotiations

30 July 2024 - The deadline for announcing how much Medicare lowered drug prices in the first year of negotiation is ...

Read more →

Novo Nordisk latest drugmaker to face setback in IRA litigation

1 August 2024 - A federal court backed the Biden administration’s Medicare drug price negotiation program on Wednesday, the latest ...

Read more →

Luye Pharma announces US FDA approval of Erzofri (paliperidone palmitate) extended release injectable suspension for treating schizophrenia and schizoaffective disorder

28 July 2024 - Luye Pharma today announced that the US FDA has approved the company's Erzofri (paliperidone palmitate) extended-release injectable ...

Read more →